7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide | 1047662-24-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 邻苯二甲酸异喹啉类
• 英文名称: 7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide
• 英文别名: (3R)-7-amino-4,5,6-triethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one
• CAS: 1047662-24-7
• 化学式: C₂₆H₃₂N₂O₈
• 分子量: 500.549
• InChiKey: IRGJVQIJENCTQF-TZIWHRDSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Pure isomers of tritoqualine
  申请人：Nicolaou Michalis

  公开号：US20070238750A1

  公开（公告）日：2007-10-11

  The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.
• Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
  申请人：Nicolaou Michalis

  公开号：US20080207530A1

  公开（公告）日：2008-08-28

  The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.
• TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST
  申请人：Loria Emile

  公开号：US20130059878A1

  公开（公告）日：2013-03-07

  The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.